enGene Therapeutics grants Duncan 500,000 options

Available on EDGAR 11/13/2026 - 04:54 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:54 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

enGene Therapeutics Inc. reported that Chief Legal & Admin Officer Jason Duncan received a stock-option award covering 500,000 common shares on November 13, 2026. The options have a $2.41-per-share exercise price and expire November 13, 2036. They vest 25% on the first anniversary of November 13, 2026, with the remainder vesting and becoming exercisable in substantially equal monthly amounts over the next three years, subject to continued service.

Insider Trade Summary

Grant/Award: 500,000 shares

Grant/Award 1 txn

Insider Duncan Jason

Role Chief Legal & Admin Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 500,000 options (Direct)

Footnotes (1)

1. F1. The stock options vest as to 25% of the total number of shares on the first anniversary of November 13, 2026, and the remainder vesting and becoming exercisable in substantially equal amounts monthly for three years thereafter, subject to the reporting person's continued service.

Key Figures

Options awarded: 500,000 options Exercise price: $2.41 per share Initial vesting: 25% +1 more

4 metrics

Options awarded 500,000 options Awarded to Chief Legal & Admin Officer Jason Duncan on November 13, 2026.

Exercise price $2.41 per share Price to exercise the options.

Initial vesting 25% Vests on the first anniversary of November 13, 2026.

Option expiration November 13, 2036 Expiration date for the options.

Key Terms

vesting, exercisable

2 terms

vesting financial

"the remainder vesting and becoming exercisable in substantially equal amounts monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercisable financial

"vesting and becoming exercisable in substantially equal amounts monthly for three years thereafter"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When do Jason Duncan’s ENGN stock options expire?

They expire on November 13, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Duncan Jason

(Last) (First) (Middle)

C/O 4868 RUE LEVY

SUITE 220

(Street)

SAINT-LAURENT H4R 2P1

(City) (State) (Zip)

QUEBEC, CANADA

(Country)

2. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal & Admin Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.41	11/13/2026		A		500,000		(1)	11/13/2036	Common Shares	500,000	$0	500,000	D

Explanation of Responses:

1. The stock options vest as to 25% of the total number of shares on the first anniversary of November 13, 2026, and the remainder vesting and becoming exercisable in substantially equal amounts monthly for three years thereafter, subject to the reporting person's continued service.

	/s/ Elizabeth Shortsleeve as attorney-in fact for Jason Duncan	11/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)